Skip to content

Released Nov 9, 2015, after the close

10-Q filed Nov 9, 2015, 40 days after period end · 0001144204-15-063825

Q3 2015 · 10-Q
Revenue$1.34M−44.2% vs Q3 2014±0.0% vs Q2 2015
Net Income-$3.82MN/M vs Q3 2014N/M vs Q2 2015
EPS Diluted-$0.04N/M vs Q3 2014N/M vs Q2 2015
Gross Profit$1,113,000−41.7%
Operating Income-$5,002,000N/M
Operating Cash Flowderived-$8,660,000N/M
Free Cash Flowderived-$8,788,000N/M
Margins · derived
Gross margin83.3%+3.6 pt vs Q3 2014
Operating margin-374.4%−115.3 pt vs Q3 2014
Net margin-285.9%+48.4 pt vs Q3 2014

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2015Q3 2014Q3 2013Q3 2012
Revenue$1.34M$2.40M$2.28M$3.72M
Net Income-$3.82M-$8.01M-$5.75M-$5.48M
EPS Diluted-$0.04-$0.09-$0.06$0.06

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR